Epidemiology, resource use, and treatment patterns of locally advanced or metastatic urothelial carcinoma in France
The substantial disease burden of la/mUC in France highlights the unmet need for new therapies.
Authors
- Sandrine Brice (ORCID: https://orcid.org/0000-0001-5298-8389)
- Torsten Strunz (ORCID: https://orcid.org/0000-0001-6032-8794)
- Florence Joly (ORCID: https://orcid.org/0000-0001-7004-9895)
- Emilie Casarotto (ORCID: https://orcid.org/0000-0003-1891-417X)
- M. Vuillet
- Roberta Minacori
- Aurore Tricotel
- Vicki Munro (ORCID: https://orcid.org/0000-0002-3125-5044)
- K.M. Leyland (ORCID: https://orcid.org/0000-0001-6999-3344)
- Anil Upadhyay
- Marc A. Thomas (ORCID: https://orcid.org/0009-0004-4665-9713)
- Morgan Rouprêt
- Stéphane Culine
Institutions
- Inserm (FR)
- Délégation Paris 7 (FR)
- Université Paris Cité (FR)
- IQVIA (United Kingdom) (GB)
- Sorbonne Université (FR)
- Astellas Pharma (China) (CN)
- Centre François Baclesse (LU)
- Astellas Pharma (United Kingdom) (GB)
- Normandie Université (FR)
- Honeywell (France) (FR)
- Centre Hospitalier Universitaire de Caen Normandie (FR)
- Hôpital Saint-Louis (FR)
- Université de Caen Normandie (FR)
Publication Details
- Journal
- Future Oncology
- Published
- 2025-02-20
- DOI
- https://doi.org/10.1080/14796694.2025.2459058
- Citations
- 1
- Primary Topic
- Bladder and Urothelial Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 2.01
Funders
- Seagen